216393-67-8

Basic information

• Product Name: 4-CHLORO-2-FLUORO-6-IODOANILINE
• Synonyms: 4-Chloro-2-fluoro-6-iodoaniline 96%;4-Chloro-2-fluoro-6-iodoaniline96%;4- chloro- 2- fluoro- 6- iodo-Benzenamine;Benzenamine,4-chloro-2-fluoro-6-iodo-;4-CHLORO-2-FLUORO-6-IODOANILINE
• CAS NO: 216393-67-8
• Molecular Formula: C₆H₄ClFIN
• Molecular Weight: 271.46
• EINECS: -0
• Mol File: 216393-67-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 39-41°C
• Boiling Point: 267.4 °C at 760 mmHg
• Flash Point: 115.5 °C
• Appearance: /
• Density: 2.089 g/cm³
• Vapor Pressure: 0.00818mmHg at 25°C
• Refractive Index: 1.665
• Storage Temp.: 2-8°C(protect from light)
• PKA: 0.51±0.10(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: 4-CHLORO-2-FLUORO-6-IODOANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2-FLUORO-6-IODOANILINE(216393-67-8)
• EPA Substance Registry System: 4-CHLORO-2-FLUORO-6-IODOANILINE(216393-67-8)

Safety Data

• Hazard Codes: Xi,T
• Statements: 20/21/22-36/38-25
• Safety Statements: 26-36/37/39-45
• RIDADR: 2811
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 216393-67-8(Hazardous Substances Data)

Usage

General Description

4-CHLORO-2-FLUORO-6-IODOANILINE is a chemical compound with the molecular formula C6H5ClFIN. It is a halogenated aniline derivative, commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and dyes. 4-CHLORO-2-FLUORO-6-IODOANILINE is characterized by the presence of chloro, fluoro, and iodo substituents attached to the benzene ring, making it a valuable building block in organic synthesis. It is important to handle this chemical with care due to its potential hazards, including its toxic and irritant properties. Additionally, it is important to store and handle this chemical in a well-ventilated area and to use appropriate personal protective equipment to minimize the risk of exposure.

InChI:InChI=1/C6H4ClFIN/c7-3-1-4(8)6(10)5(9)2-3/h1-2H,10H2

Upstream product

• 57946-56-2 2-fluoro-4-chloroaniline 

Downstream Products

• 383132-37-4 5-chloro-7-fluoro-1H-indole-2-carboxylic acid 
• 1093942-90-5 (S)-4-benzyl-3-(5-chloro-7-fluoro-1H-indol-2-yl)oxazolidin-2-one 
• 1202551-89-0 4-chloro-2-fluoro-6-pyridin-3-ylethynyl-phenylamine 
• 1258504-28-7 N-(2-(5-chloro-7-fluoro-2-(triethylsilyl)-1H-indol-3-yl)ethyl)-5-(2,5-difluorobenzyl)isoxazole-3-carboxamide 
• 1297275-38-7 2-(3-(3-Benzyl-4-oxo-3,4-dihydrophthalazin-1-yl)-5-chloro-7-fluoro-2-methyl-1H-indol-1-yl)acetic acid 
• 1297282-80-4 4-chloro-2-fluoro-6-(prop-1-ynyl)aniline 
• 1374581-32-4 4-(6-chloro-4-fluorobenzothiazol-2-yl)-N,N-dimethylaniline 
• 1382991-58-3 N-(2-(5-chloro-7-fluoro-2-(triethylsilyl)-1H-indol-3-yl)ethyl)-4-(3-fluorobenzyl)benzamide 
• 1297286-11-3 C₂₃H₁₉ClFN₃O₃ 
• 1297275-36-5 2-(3-(1-benzyl-6-oxo-1,6-dihydropyridazin-3-yl)-5-chloro-7-fluoro-2-methyl-1H-indol-1-yl)acetic acid 
• 1421704-89-3 (6-chloro-4-fluorobenzo[d]thiazol-2-yl)(phenyl)methanone 

Relevant articles and documents

INHIBITORS OF PROTEIN ARGININE DEIMINASES

Provided herein are inhibitors of protein arginine deiminases (PADs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases

New classes of CRTH2 antagonists, the pyridazine linker containing indole acetic acids, are described. The initial hit 1 had good potency but poor permeability, metabolic stability, and PK. Initial optimization led to compounds of type 2 with low oxidative metabolism but poor oral bioavailability. Poor permeability was identified as a liability for these compounds. Addition of a linker between the indole and diazine moieties afforded a series with good potency, low rates of metabolism, moderate permeability, and good oral bioavailability in rodents. 32 was identified as the development track candidate. It was potent in cell based, binding, and whole blood assays and exhibited good PK profile. It was efficacious in mouse models of contact hypersensitivity (1 mg/kg b.i.d.) and house dust (20 mg/kg q.d.) when dosed orally. In sheep asthma, administration at 1 mg/kg iv completely blocked the LAR and AHR and attenuated the EAR phase.